Healthcare and pharma leaders have spent years navigating uncertainty, but 2026 is bringing something different. Policy shifts are no longer occasional events that require tactical adjustments-now, they're becoming a regular defining force behind pricing strategy, market access, evidence requirements, and long-term portfolio planning.
From Medicare drug price negotiations and implications of the Inflation Reduction Act to growing payer scrutiny, regulatory change, and market volatility, healthcare organisations are facing a new reality where evidence strategies built for yesterday's environment may not be enough for tomorrow's decisions.
The Cost of Standing Still
Pricing flexibility is narrowing. Regulatory timelines are becoming less predictable. Payers are demanding stronger comparative and real-world evidence. Supply-chain disruption and tariff exposure are influencing market access and prescribing behaviour.
All of this and more means research can no longer be static or purely descriptive and instead must become faster, more adaptive, more scenario-driven, and more closely tied to business-critical decisions. Organisations that continue treating evidence generation as an annual planning exercise risk reacting too slowly to policy and market changes. Instead, those that adapt fastest will be best positioned to succeed.
The Shifts Defining Successful Evidence Strategies
The assumptions that guided evidence generation just a few years ago may no longer be enough. As policy, access, and reimbursement pressures continue to evolve, healthcare and pharmaceutical organisations are being forced to rethink how they plan, prioritise, and generate evidence.
Success will increasingly depend on an organisation's ability to adapt, respond to uncertainty, and ensure that evidence strategies remain aligned with changing market realities.
The Competitive Advantage Few Organisations Are Talking About
Policy disruptions create uncertainty, but they also create opportunity.
Organisations that can translate evolving market conditions into decision-grade evidence will be better positioned in future to protect access, defend value, and strengthen long-term growth.
The ability to generate policy-aware insights quickly may become one of the most important competitive advantages in healthcare research over the next several years.
Download the full "Policy Whiplash & Pharma's Next Chapter" report to explore the key policy shifts shaping healthcare in 2026 and the actions leaders can take today to build more resilient evidence strategies.
Download the full report
